The analysis found no new safety concerns with prolonged observation and reported that AEs occurred in 52.6 percent of patients treated with Repatha and SOC during year four compared to 79.3 percent during year one. The annualized AE rates in the Repatha and SOC group versus SOC alone were 2.8 percent versus 4.0 percent for new onset diabetes, 0.4 percent versus 0 percent for neurocognitive events, and 4.7 percent versus 8.5 percent for muscle-related events. The percentage of patients who discontinued Repatha due to AEs was 0.5 percent in year four and 2.8 percent in year one.